Deepak K Pruthi, MD, FRCSC, MSCI-TS

Dr. Deepak Pruthi is an Associate Professor at the University of Texas Health San Antonio. Born in Texas he moved gradually moved north ultimately settling down in Canada where he spent his formative years. He graduated from the University of Winnipeg (BSc & BA). He went to medical school at the University of Manitoba where he obtained his MD and a medical research degree (BSc Med). He subsequently completed his Urology Surgical residency at the University of Manitoba. Following this, he then moved back to San Antonio to complete his Society of Urologic Oncology (SUO)-approved fellowship in Urologic Oncology and concurrently obtained his Master in Clinical and Translational Investigation. Following his Fellowship, he remained in San Antonio to build upon the successes of the kidney cancer program.

Dr. Pruthi’s clinical interests include Urologic Oncology focusing primarily on the treatment of kidney cancer, IVC tumor thrombus, testicular cancer (including retroperitoneal lymphadenectomy -RPLND), bladder cancer, penile cancer (including inguinal node dissection), and adrenal tumors.

He performs advanced Robotic, Laparoscopic, Endoscopic, and challenging Open surgical cases. In addition, he performs complex upper urinary tract reconstructive surgery (including ureteral reimplant, pyeloplasty, buccal mucosal onlay). He frequently operates with his colleagues in Colorectal surgery, Surgical oncology, and Gynecologic oncology often performing multidisciplinary surgery such as pelvic exenteration and large tumor resections.

His primary research interests include kidney cancer, anatomic and pathologic-based predictive modeling, oncologic outcomes, and examining the role of systemic therapy in early/locally advanced stages of urologic cancer. He participates in translational research (building tissue microarrays to identify potential targets/mutational aberrations). He believes in collaborative research having published the most heterogeneously diverse retrospective in kidney cancer identifying diabetes and obesity as risk factors for high risk kidney cancer (https://riskcalc.org/KidneyUpstaging/). A member of the Southwest Oncology Group (SWOG) and UT he is active in clinical trials to identify new agents for the treatment of genitourinary malignancies. 

He is committed to patient care and serves on a number of committees to coordinate and improve the standard of cancer care delivery.